Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox
Explore this paper's citation graph
Summary
The unique cardioprotective benefits of ACEIs are also observed in patients with diabetes mellitus, who may or may not have coexistent atherosclerosis, and are considered a first priority in macrovascular risk reduction by the Canadian Diabetes Association and others.
- Type
- article
- Published
- 2006-08-22
- Cited by
- 256
- References
- 119
- Access
- Open access
- OpenAlex
- https://openalex.org/W2001722069
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3036358
Keywords
Medicine, Myocardial infarction, Cardiology, Angiotensin Receptor Blockers, Internal medicine
References
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
- Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
- The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
- The adult with congenital heart disease: born to be bad?
- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
- Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.
- Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
- Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
- ACE inhibition in stable coronary artery disease.
- Role of bradykinin in preconditioning and protection of the ischaemic myocardium
- Angiotensin AT2 receptors: cardiovascular hope or hype?
- Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial
- Renin-angiotensin system modulation: the weight of evidence.
- Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.
- The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial
- Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
- ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
- Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function.
- What is in the differential diagnosis of a B-type natriuretic peptide level of 1,000 pg/ml?
- Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds
Cited by
- Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease
- Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials
- Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis
- An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology
- Ventajas potenciales de aliskiren, el primer inhibidor de la renina
- Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism
- The influence of ACE (I/D) polymorphism in cardiovascular disease
- ACEIs for cardiovascular risk reduction--have we taken our eye off the ball?
- Der Einfluss des Angiotensin II-Rezeptorsubtyp 2 auf das kardiovaskuläre Remodeling nach experimentellem Myokardinfarkt
- The Comparative Effectiveness of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes
- Innovaciones en el tratamiento antihipertensivo en el adulto mayor
- B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy.
- Et and diabetic nephropathy: preclinical and clinical studies.
- The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action
- A vaccine for hypertension
- MANAGEMENT AND TREATMENT OF Chronic Kidney Disease
- Effects of an N-Type Calcium Antagonist on Angiotensin II-Renin Feedback
- Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
- BP Goal Achievement in Patients with Uncontrolled Hypertension
- Aplicaciones del estudio ONTARGET a la práctica clínica
Related papers
- Measuring the incidence of acute myocardial infarction: the problem of possible acute myocardial infarction.
- 5-year mortality rate in patients with suspected acute myocardial infarction in relation to early diagnosis.
- The renin and iso-renin-angiotensin system in rats with experimental pitutary tumors (38585).
- The second myocardial infarction: Is there any difference in symptoms and prehospital delay compared to the first myocardial infarction?
- Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain.
- Role of angiotensin III in the regulation of blood pressure, plasma aldosterone and plasma renin activity in rabbit.
- Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial.